Loading...
•
Jun 30
Gyre Therapeutics Q2 2025 Earnings Report
Estimated Revenue:$NaN
Estimated EPS:$NaN
Key Takeaways
Gyre Therapeutics posted Q2 2025 revenue of $26.8 million and net income of $1.6 million. Earnings were supported by the successful launch of Etorel and continued rollout of Contiva in the PRC. Operating income declined year-over-year due to higher marketing and administrative costs.
Revenue reached $26.8 million, up from $25.2 million a year ago, due to new product launches.
Net income fell to $1.6 million from $4.5 million in Q2 2024 due to increased operating expenses.
Cash, short-term deposits, and CDs totaled $75.9 million at quarter-end.
Sales in the PRC were driven by Etuary ($23.5M), Etorel ($1.6M), and Contiva ($1.5M).
Gyre Therapeutics
Gyre Therapeutics
Gyre Therapeutics Revenue by Segment
Gyre Therapeutics Revenue by Geographic Location
Revenue by Segment
License & Collaboration Revenue
CapyFin.comRevenue by Geographic Location
PRC Revenue
CapyFin.com Forward Guidance
Gyre anticipates revenue growth for the remainder of 2025 driven by continued product launches in the PRC and expansion into new indications.
Positive Outlook
- Projected full-year 2025 revenue of $118–128 million.
- Phase 3 success of Hydronidone supports future filings in PRC.
- Ongoing U.S. expansion with Phase 2 trial of Hydronidone for MASH expected in 2H 2025.
- Launch of Etorel and Contiva is contributing to commercial momentum.
- Strong cash reserves support R&D and commercialization plans.
Challenges Ahead
- Net income declined year-over-year due to higher operating costs.
- Income from operations decreased by $1.0 million vs. Q2 2024.
- G&A expenses rose by $1.4 million from prior year.
- Continued reliance on PRC market for all reported revenue.
- Sales of flagship drug Etuary declined YoY by $1.6 million.
Loading...
Key Statistics
Market Cap
$703M
P/E Ratio
-6.13
Sector
Health Technology
Industry
Pharmaceuticals Major
52-Week High
$16.5
52-Week Low
$6.42
R&D Expenses
$3.43M
G&A Expenses
$4.83M